The proposed developmental funds constitute an invaluable flexible funding source for the UCCC to pursue the initiatives and research opportunities identified though the planning and evaluation activities of the Cancer Center. The UCCC proposes to use these funds to 1) strengthen scientific programs, 2) support faculty recruitment in areas of strategic focus and need, 3) provide both junior and more established investigators the opportunity to explore research ideas of particular innovation and collaboration through pilot grant program funds, and 4) support the development of two new shared resources. Specifically, the UCCC proposes to allocate $200K per year in support of recruitment for seven faculty: Associate Director for Basic Science;senior breast and prostate cancer investigator;senior bladder cancer biologist;senior metastasis investigator and senior immunologist for the developing Metastasis and Tumor Microenvironment Program;and Program Co-leader for Cancer Cell Biology. An annual budget of $200K is proposed in support of the broad-based and diverse UCCC Pilot Grant Programs. A budget of $100K is proposed for each of two developing shared resources: 1) Preclinical Animal Services SR and 2) Human Research Imaging. Funding for these proposed projects totals $600K per year. For all categories of the request, the proposed funds will be supplemented to significant degrees by other institutional sources of funds. In summary, these funds provide a means to pursue the particulariy new and innovative initiatives, not generally funded by established sponsored research entities that potentiate Center-defining areas of scientific research.
An NCl-designated Comprehensive Cancer Center, the UCCC is dedicated to the discovery of the nature of cancer and the development of more effective approaches to prevention, diagnosis and therapy. The requested Developmental funds provide flexibility to recruit faculty, fund pilot grants, and develop shared resources that strengthen the UCCC's research programs.
|Saichaemchan, S; Ariyawutyakorn, W; Varella-Garcia, M (2016) Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy. Curr Mol Med 16:40-62|
|Gillen, Austin E; Yamamoto, Tomomi M; Kline, Enos et al. (2016) Improvements to the HITS-CLIP protocol eliminate widespread mispriming artifacts. BMC Genomics 17:338|
|Justice, Cristina M; Bishop, Kevin; Carrington, Blake et al. (2016) Evaluation of IRX Genes and Conserved Noncoding Elements in a Region on 5p13.3 Linked to Families with Familial Idiopathic Scoliosis and Kyphosis. G3 (Bethesda) 6:1707-12|
|Eckwahl, Matthew J; Arnion, Helene; Kharytonchyk, Siarhei et al. (2016) Analysis of the human immunodeficiency virus-1 RNA packageome. RNA 22:1228-38|
|Iguchi, Nao; Malykhina, Anna P; Wilcox, Duncan T (2016) Inhibition of HIF Reduces Bladder Hypertrophy and Improves Bladder Function in Murine Model of Partial Bladder Outlet Obstruction. J Urol 195:1250-6|
|Seedorf, Gregory; Metoxen, Alexander J; Rock, Robert et al. (2016) Hepatocyte growth factor as a downstream mediator of vascular endothelial growth factor-dependent preservation of growth in the developing lung. Am J Physiol Lung Cell Mol Physiol 310:L1098-110|
|Agarwal, Neeraj; Dancik, Garrett M; Goodspeed, Andrew et al. (2016) GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis. Cancer Res 76:5175-85|
|Helfrich, Barbara A; Kim, Jihye; Gao, Dexiang et al. (2016) Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther 15:2314-2322|
|Munson, Daniel J; Egelston, Colt A; Chiotti, Kami E et al. (2016) Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. Proc Natl Acad Sci U S A 113:8272-7|
|Scott, Aaron J; Lieu, Christopher H; Messersmith, Wells A (2016) Therapeutic Approaches to RAS Mutation. Cancer J 22:165-74|
Showing the most recent 10 out of 1302 publications